Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels.

Authors: Sanchez-Correa, B  Bergua, JM  Campos, C  Gayoso, I  Arcos, MJ  Banas, H  Morgado, S  Casado, JG  Solana, R  Tarazona, R 
Citation: Sanchez-Correa B, etal., Cytokine. 2013 Mar;61(3):885-91. doi: 10.1016/j.cyto.2012.12.023. Epub 2013 Jan 26.
Pubmed: (View Article at PubMed) PMID:23357299
DOI: Full-text: DOI:10.1016/j.cyto.2012.12.023

BACKGROUND: Several evidences support the existence of cytokine deregulation in acute myeloid leukemia (AML) patients that may be associated with pathogenesis, disease progression and patient survival. METHODS: In the present study, we analyzed plasma levels of pro- and anti-inflammatory cytokines in AML patients and age-matched healthy donors. TNF-alpha, IL-6, IL-1beta, IL-2, IFN-gamma, IL-17A, IL-12p70, IL-8, IL-10, IL-4 and IL-5 were analyzed using fluorescent bead-based technology and TGF-beta by ELISA technique. Because age-associated differences in cytokine profiles have been described, patients and healthy individuals were divided into two age groups: up to 65 years and over 65 years. RESULTS: Our results showed that plasma TNF-alpha, IL-6 and IL-10 levels were higher in AML patients from both groups of age. IL-8 was increased in AML patients less than 65 years while the plasma concentrations of IL-4, IL-5 and IL-12p70 were significantly higher only in elderly AML patients compared with aged-matched healthy controls. Moreover, plasma levels of IL-6 and IL-10 were associated with patient survival and event-free survival. CONCLUSIONS: An aberrant production of the pro-inflammatory cytokines IL-6 and TNF-alpha and the anti-inflammatory cytokine IL-10 is observed in AML patients. Low levels of IL-6 and high levels of IL-10 represent favorable prognostic factors for survival in AML patients. These results support the idea that cytokine deregulation may be useful as a marker for predicting clinical evolution in AML patients.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11046264
Created: 2016-04-04
Species: All species
Last Modified: 2016-04-04
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.